

Meeting: Utilization Management Committee	Date: 4/18/2024
Title/Topic: Medical Policy – Tumor Treatment Field Therapy (TTF)	Policy Number: n05676
Purpose: Annual Review	Outcome: Accept as proposed
Line of Business: Commercial and Medicare	Effective Date: 4/18/2024

INTRODUCTION:

Includes definition of problem or opportunity. Provides background information on the topic. Describes current state. May also include prior state and/or factors that have changed. Includes operational definitions where key terms may have varied interpretation.

Tumor Treatment Field (TTF) is electrical therapy delivered by a portable device that creates alternating low-intensity, intermediate-frequency electric fields that inhibit cell mitosis, interfering with cell division and organelle assembly for individuals with histologically confirmed glioblastoma multiforme (GBM). The treatment involves delivering alternating electrical field therapy through 4 adhesive patches, called transducer arrays, applied to the scalp, and powered through the connection cable and box, which is powered by a battery. The objective is to provide continuous action against disease progression by delivering Tumor Treatment Fields to selectively disrupt mitosis in dividing cancer cells. Treatment protocol includes 18 hours of use per day for a minimal treatment time span of 4 weeks. Evidence suggests that TTF therapy results in overall survival and progression-free survival at least equivalent to chemotherapy in individuals with recurrent GBM and increased overall survival and progression-free survival in individuals with newly diagnosed GBM compared to Temozolomide (TMZ) alone.

This medical policy provides guidance for Utilization Management Coordinator Registered Nurses (UMC-RN) regarding determinations involving the medical necessity of tumor treating field for the treatment of glioblastoma multiforme. This policy is due for annual review.

ACTION RECOMMENDED:

States recommendations in specific terms. Includes a summary of what should be accomplished, methods, and timetable (if applicable). Recommendations on implementation and follow-up plans may also be included.

Annual review has been conducted and the Tumor Treating Field Therapy medical policy is presented for review and approval as written.

No changes were made to the intention or utilization of this policy. Annual review was performed, a review and update of references was conducted, and CPT code verification was completed.

ANALYSIS/JUSTIFICATION:

Includes information relevant to the recommended action including information used in formulation the recommendations. Information will include reference to any existing Centers for Medicare & Medicaid Services (CMS) coverage determinations as well as any existing established vendor criteria. Information may include financial/cost data, service measures, projections or other key measures or process tools, recommendations from a clinical provider with expertise regarding the topic, and/or information from other widely used treatment guidelines or peer reviewed clinical literature.

Centers for Medicare and Medicaid Services (CMS) has a Local Coverage Determination Tumor Treatment Field Therapy (L34823) which speaks to initial and continued coverage of the device for glioblastomas.

MCG 28th edition provide guidelines for initial use of the tumor treatment field therapy but does not speak to the continue used.

REFERENCES:

Includes detailed description regarding source(s) of information used for development of policy or recommendations via citation.

- Centers for Medicare & Medicaid Services: Local Coverage Determination (LCD): Tumor Treatment Field Therapy (TTFT) (L34823) 1/1/2020
- MCG Ambulatory Care 28th edition Guidelines, Alternating Electric Field Therapy A-0930 (AC)
- NCCN Guidelines Version 1.2023 March 24,2023: Central Nervous System Cancers: Adult Glioma (Glio-A 4 & 5 of 8)

REVISION REASON:

Includes the date changes or updates were made and summary of changes applied.

04/18/2024 annual review, grammar and formatting updates, references updated

Disclaimer:

Contract language as well as state and federal laws take precedence over any medical policy.

Network Health coverage documents (i.e. Certificate of Coverage, Evidence of Coverage, Summary Plan Descriptions) outline contractual terms of the applicable benefit plan for each line of business and will be considered first in determining eligibility. Not all Network Health coverage documents are the same. Coverage may differ. Our Medicare membership follows applicable Centers for Medicare and Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD) and Local Coverage Determinations (LCD). Please refer to the CMS website at www.cms.gov.

Network Health reserves the right to review and update our medical policies on occasion as medical technologies are constantly evolving. The documentation of any brand name of a test, product and/or procedure in a medical policy is in no way an endorsement of that product; it is for reference only.

Network Health's medical policies are for guidance and not intended to prevent the judgment of the reviewing medical director(s) nor dictate to health care providers how to practice medicine.